Abstract
Background:
The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.
Methods:
Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed.
Results:
Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events.
Conclusion:
Week 96 data confirm week 48 observations in MERIT.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Alkynes
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use*
-
Benzoxazines / adverse effects
-
Benzoxazines / therapeutic use*
-
CCR5 Receptor Antagonists
-
Cyclohexanes / adverse effects
-
Cyclohexanes / therapeutic use*
-
Cyclopropanes
-
Drug Therapy, Combination
-
Female
-
HIV Fusion Inhibitors / adverse effects
-
HIV Fusion Inhibitors / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / virology
-
HIV-1*
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / therapeutic use*
-
Male
-
Maraviroc
-
Middle Aged
-
Treatment Outcome
-
Triazoles / adverse effects
-
Triazoles / therapeutic use*
-
Zidovudine / adverse effects
-
Zidovudine / therapeutic use*
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
Cyclopropanes
-
HIV Fusion Inhibitors
-
Triazoles
-
Lamivudine
-
Zidovudine
-
efavirenz
-
Maraviroc